Atika Capital Management LLC Makes New $2.32 Million Investment in Heartflow, Inc. $HTFL

Atika Capital Management LLC acquired a new stake in shares of Heartflow, Inc. (NASDAQ:HTFL) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 69,000 shares of the company’s stock, valued at approximately $2,323,000. Atika Capital Management LLC owned about 0.08% of Heartflow at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in the company. TFC Financial Management Inc. purchased a new position in Heartflow in the 3rd quarter worth $40,000. Legal & General Group Plc purchased a new stake in shares of Heartflow in the third quarter worth about $59,000. Y Intercept Hong Kong Ltd acquired a new stake in shares of Heartflow during the 3rd quarter worth approximately $234,000. Legato Capital Management LLC purchased a new position in shares of Heartflow in the 3rd quarter valued at about $243,000. Finally, TrueMark Investments LLC purchased a new stake in shares of Heartflow in the third quarter valued at approximately $918,000.

Wall Street Analyst Weigh In

HTFL has been the subject of a number of research analyst reports. Canaccord Genuity Group reissued a “buy” rating and set a $40.00 target price on shares of Heartflow in a report on Monday. Weiss Ratings reiterated a “sell (d)” rating on shares of Heartflow in a report on Monday, December 29th. Stifel Nicolaus lifted their target price on Heartflow from $35.00 to $40.00 and gave the company a “buy” rating in a research report on Thursday, November 13th. Wells Fargo & Company initiated coverage on Heartflow in a research note on Wednesday, January 28th. They issued an “overweight” rating and a $38.00 price target on the stock. Finally, JPMorgan Chase & Co. raised their price objective on Heartflow from $36.00 to $40.00 and gave the stock an “overweight” rating in a research report on Thursday, November 13th. Five analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $38.50.

Insider Buying and Selling at Heartflow

In other news, CEO John C.M. Farquhar sold 22,562 shares of Heartflow stock in a transaction on Tuesday, February 10th. The stock was sold at an average price of $27.46, for a total value of $619,552.52. Following the completion of the sale, the chief executive officer directly owned 591,656 shares of the company’s stock, valued at approximately $16,246,873.76. The trade was a 3.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder Bain Capital Life Sciences Inv sold 2,000,000 shares of the business’s stock in a transaction on Wednesday, February 4th. The shares were sold at an average price of $28.05, for a total value of $56,100,000.00. Following the completion of the sale, the insider owned 10,448,158 shares in the company, valued at $293,070,831.90. This represents a 16.07% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 2,104,837 shares of company stock valued at $58,761,759.

Heartflow Stock Performance

Heartflow stock opened at $22.21 on Thursday. The company has a market capitalization of $1.89 billion and a PE ratio of -12.27. Heartflow, Inc. has a fifty-two week low of $20.13 and a fifty-two week high of $41.22. The firm has a 50 day moving average price of $28.00 and a 200 day moving average price of $30.83.

Heartflow Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.